Final answer:
The statement implies that the cost of treating 1 case of Hepatitis C with Harvoni is equivalent to the cost of sustaining the 4 A program for approximately 1 year. This suggests that the cost of Harvoni treatment is significantly high, potentially indicating that the cost-effectiveness of the 4 A program is significantly higher.
Step-by-step explanation:
This statement implies that the cost of treating 1 case of Hepatitis C with Harvoni is equivalent to the cost of sustaining the 4 A program for approximately 1 year. This suggests that the cost of Harvoni treatment is significantly high, potentially indicating that the cost-effectiveness of the 4 A program is significantly higher. It does not provide information about the proportionality of the cost of Harvoni treatment to the annual budget of the 4 A program, nor does it suggest that the 4 A program is less sustainable economically compared to individual treatments for Hepatitis C.